Ligelizumab for chronic spontaneous urticaria*
- 30 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 183 (5), 829-830
- https://doi.org/10.1111/bjd.18901
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Ligelizumab for Chronic Spontaneous UrticariaNew England Journal of Medicine, 2019
- New treatments for chronic urticariaAnnals of Allergy, Asthma & Immunology, 2019
- Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticariaAllergology International, 2018
- The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticariaAllergy, 2018
- The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their changeAllergy, 2017
- Autoimmune chronic spontaneous urticaria: What we know and what we do not knowJournal of Allergy and Clinical Immunology, 2017
- Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responsesJournal of Allergy and Clinical Immunology, 2016
- Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trialsJournal of Allergy and Clinical Immunology, 2016
- BSACI guideline for the management of chronic urticaria and angioedemaClinical and Experimental Allergy, 2015